NCT00301899已完成2 期
A Phase II Study to Evaluate the Efficacy and Safety Using Combined Monoclonal Antibodies, Trastuzumab and Pertuzumab in Subjects With Her-2 Overexpressed Locally Advanced and Metastatic Breast Cancer
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 37
- 试验地点
- 2
- 主要终点
- Safety
研究概览
简要总结
RATIONALE: Monoclonal antibodies, such as trastuzumab and pertuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving trastuzumab together with pertuzumab may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving trastuzumab together with pertuzumab works in treating patients with unresectable locally advanced or metastatic breast cancer that did not respond to previous trastuzumab.
详细描述
OBJECTIVES:
Primary
- Determine the objective response rate in patients with HER2/neu-overexpressing, inoperable locally advanced or metastatic breast cancer refractory to trastuzumab (Herceptin®)-based therapy treated with trastuzumab and pertuzumab.
- Determine the safety and tolerability of this regimen in these patients.
Secondary
- Determine the time to progression, progression-free survival, duration of response, and the percentage of patients free from disease progression at 3, 6, and 12 months.
- Correlate pre-treatment HER-2/neu phosphorylation and the phosphorylation of downstream markers of signaling pathways using tumor tissue and blood with pertuzumab sensitivity and/or trastuzumab resistance in these patients.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically confirmed invasive breast cancer of 1 of the following stages:
- •Metastatic disease (stage IV)
- •Inoperable locally advanced disease
- •Disease progression after prior neoadjuvant chemotherapy required
- •Disease progression on or after trastuzumab (Herceptin®) based-therapy
- •Received 1-3 prior trastuzumab-based regimens
- •HER2/neu-positive tumor, defined as 3+ by fluorescent in situ hybridization
- •Measurable disease, defined as at least 1 lesion that can be measured in at least one dimension
- •No clinical signs or symptoms of brain and/or leptomeningeal metastases confirmed by CT scan or MRI
- •Brain and/or leptomeningeal metastases allowed if patient has stable lesions after standard treatment (surgery or radiotherapy), is asymptomatic on neurological exam, and is not receiving corticosteroid therapy to control symptoms
- •Hormone receptor status:
- •Not specified
- •PATIENT CHARACTERISTICS:
- •ECOG performance status 0-1
- •Male or female
- •Menopausal status not specified
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception
- •Absolute neutrophil count ≥ 1,500/mm^3
- •Platelet count ≥ 75,000/mm^3
- •Creatinine ≤ 1.5 times upper limit of normal (ULN)
- •Bilirubin ≤ 1.5 times ULN
- •Alkaline phosphatase < 5 times ULN
- •AST and ALT ≤ 2.5 times ULN (5 times ULN if liver metastases are present)
- •LVEF above lower limit of normal by echocardiogram or MRI
- •No clinical signs or symptoms of heart failure
- •No uncontrolled hypertension (i.e., blood pressure ≥ 180/100 mm Hg)
- •No significant valvular disease (i.e., aortic or mitral regurgitation of 3 or 4+/4+ severity or stenosis of either valve)
- •No history of uncontrolled cardiac arrhythmia
- •No symptomatic or asymptomatic myocardial infarction
- •No angina pectoris requiring medication
- •No other documented significant cardiac event
- •No poorly controlled diabetes mellitus (i.e., fasting blood sugar ≥ 200 mg/dL)
- •No history of hypersensitivity reaction to trastuzumab
- •No nonmalignant condition requiring ≥ 20 mg of prednisone (or equivalent)
- •No other malignancy within the past 5 years except carcinoma in situ of the cervix or nonmelanoma skin cancer
- •No ongoing liver disease, including viral or other hepatitis, alcohol abuse, or cirrhosis
- •No other serious medical illness
- •No medical or psychiatric condition that would preclude study participation
- •PRIOR CONCURRENT THERAPY:
- •See Disease Characteristics
- •Recovered from prior therapy
- •More than 3 weeks since prior investigational anticancer agents
- •More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C), major surgery, or immunotherapy
- •More than 4 weeks since prior radiotherapy except short-course palliative radiotherapy for bone pain
- •More than 2 weeks since prior and no concurrent oral hormonal therapy
- •More than 4 weeks since prior fulvestrant
- •No prior doxorubicin hydrochloride or doxorubicin HCl liposome at a cumulative dose of > 360 mg/m^2
- 另有 4 项未显示
排除标准
- 未提供
结局指标
主要结局
Safety
Minimal rate of clinical responses
次要结局
- Time to progression
- Time to response
- Response duration
- Progression-free survival
研究者
研究点 (2)
Loading locations...
相似试验
终止
2 期
Trastuzumab With or Without Everolimus in Treating Women With Breast Cancer That Can Be Removed By SurgeryBreast CancerNCT00674414UNICANCER82
已完成
1 期
Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal CancerAdenocarcinoma of the ColonAdenocarcinoma of the RectumRecurrent Colon CancerRecurrent Rectal CancerStage III Colon CancerStage III Rectal CancerStage IV Colon CancerStage IV Rectal CancerNCT00551421National Cancer Institute (NCI)17
已完成
1 期
Cetuximab and Trastuzumab in Treating Patients With Metastatic Pancreatic Cancer That Progressed After Previous Treatment With GemcitabinePancreatic CancerNCT00923299Institut du Cancer de Montpellier - Val d'Aurelle33
已完成
2 期
Trastuzumab and Capecitabine in Treating Women With Metastatic Breast CancerBreast CancerNCT00107393Tohoku University75
Unknown
2 期
Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal CancerMetastatic CancerColorectal CancerNCT00438737European Organisation for Research and Treatment of Cancer - EORTC100